Congress reauthorizes Rare Pediatric Disease PRV program, preserving Atossa Therapeutics' DMD voucher eligibility

Congress reauthorization preserves voucher path for Atossa's DMD candidate

Atossa Therapeutics says a five‑year reauthorization of the Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) Program preserves its eligibility to receive a voucher if the U.S. Food and Drug Administration approves (Z)-endoxifen for Duchenne muscular dystrophy (DMD). The company, which notes Congress announced the renewal on Feb. 4, 2026 and Atossa reaffirmed its position on Feb. 5, says the RPD designation it secured late last year keeps the program’s non‑dilutive regulatory incentive intact. Under the RPD framework, a qualifying approval can generate a PRV that may be used to obtain priority review for a later application or be sold or transferred.

Atossa frames the renewal as validation of both the regulatory path and the underlying science for (Z)-endoxifen as a potential DMD treatment and a broader platform across oncology and rare diseases. President and CEO Steven Quay, M.D., Ph.D., emphasizes the urgent need for alternatives to chronic steroids and for therapies that do not rely on exon‑specific gene targeting, while Senior Vice President of R&D Janet Rea, MSPH, highlights encouraging preclinical results and the drug’s potential to treat DMD broadly because it does not target particular exon defects. The company references prior investigational new drug (IND) clearances for exon‑skipping approaches as context for advancing toward clinical testing in boys living with DMD.

Strategically, Atossa says the preservation of PRV eligibility maintains options to accelerate development, seek collaborators, and engage with regulators while continuing to prioritize patient safety and the generation of clinical data. The company frames the congressional action as Congressional recognition of the costs and complexities of developing therapies for rare pediatric diseases and as a mechanism that sustains potential non‑dilutive value creation as its DMD program progresses toward clinical milestones.

Valuation and regulatory mechanics

Atossa notes disclosed PRV transactions over the past 18 months range from about $150 million to $200 million, underscoring the financial optionality a voucher can represent for a small clinical‑stage biopharma pursuing costly late‑stage development without dilutive financing.

Platform and next steps

The company continues to position (Z)-endoxifen as both a DMD candidate and a platform asset across oncology and rare diseases, saying preserved PRV eligibility supports partnership discussions and future regulatory interactions as it plans to move the program into clinical testing.